MUSTANG BIO, INC. MBIO Cash Flow

Mustang bio, inc. (MBIO)

CashFlow / Quarterly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16
Cash Flows from Operating Activities:
Net loss
-11,857	-16,209	-10,168	-10,399	-9,613	-11,770	-7,518	-5,093	-6,281	-15,601	-6,940	-5,529	-3,218	-8,748	-1,870	-1,133	-903
Issuance of common shares - Equity fee on At-the-Market Offering to Fortress Biotech
125	0	0	495	0	-	-	-	-	-	-	-	-	-	-	-	-
Issuance of common shares - Equity fee on Horizon Notes to Fortress Biotech
0	0	0	0	375	0	0	0	0	-	-	-	-	-	-	-	-
Research and development - licenses acquired
250	-	-	-	450	-	-	-	-	-	-	-	-	-	-	-	-
Research and development - licenses acquired
250	0	700	200	450	-	-	-	-	-	-	-	-	-	-	-	-
Stock-based compensation expenses
805	490	1,120	622	432	1,091	903	971	1,995	782	833	397	0	-	-	-	-
Depreciation expense
400	400	300	300	300	300	200	93	7	2	0	0	0	-	-	-	-
Research and development - licenses acquired
-	-	-	-	-	-	-	-	75	-	-	-	-	-	-	-	-
Research and development - licenses acquired
-	-	-	-	-	-	-	-	-	500	300	1,500	575	0	0	0	0
Issuance of common shares - Founders Agreement
-	-	-	-	-	-	-	-	-	0	2	0	1,232	588	274	0	0
Accretion of debt discount
259	244	234	232	0	-	-	-	-	-	-	-	-	-	-	-	-
Amortization of operating lease right-of-use assets
31	30	15	35	30	0	0	0	0	-	-	-	-	-	-	-	-
Adjustments to reconcile net loss to net cash used in operating activities:
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
-	-	-	-	-	-	-	129	828	-	-	-	-	-	-	-	-
Prepaid expenses and other current assets
246	-	-	-	-265	-	-	-	-	-	406	-7	15	-	-	-	-
Prepaid expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0
Interest receivables
-	-	-	-	-	-	-	-	-	71	35	0	0	-	-	-	-
Other receivables - related party
-5	-36	-73	17	111	-50	50	0	0	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-163	-	-	-	1,031	-	-	-	-	-	-	-	-	-	-	-	-
Accounts payable and accrued expenses
-	-	-	-	-	-	982	942	-787	-591	-372	2,412	-117	-357	714	195	116
Payable and accrued expenses - related party
-50	312	-475	141	382	-39	88	-129	179	68	-69	123	-110	-625	125	125	125
Accrued interest - related party
-	-	-	-	-	-	-	-	-	0	0	-2	-411	-33	104	93	81
Deferred rent
-	-	-	-	-	-271	-75	-270	-75	-50	0	0	0	-	-	-	-
Lease liabilities
-316	48	-129	16	12	0	0	0	0	-	-	-	-	-	-	-	-
Notes payable - related party
-	-	-	-	-	-	-	-	-	-	-	118	28	-	-	0	0
Net cash used in operating activities
-10,152	-9,490	-8,830	-8,778	-6,483	-6,523	-3,800	-3,356	-5,565	-5,167	-4,771	-974	-2,036	-	-	-	-
Cash Flows from Investing Activities:
Net cash used in operating activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-720	-581
Purchase of short-term investment (certificates of deposit)
-	-	-	-	-	5,000	12,500	10,000	25,000	11,914	14,050	20,038	0	-	-	-	-
Maturity of certificate of deposit
0	-	-	-	12,500	-	-	-	-	-	-	-	-	-	-	-	-
Maturity of certificate of deposit
-	-	-	-	-	-	-	12,002	14,000	20,000	0	0	0	-	-	-	-
Purchase of research and development licenses
0	500	400	250	200	0	1,000	0	75	0	1,800	200	375	0	0	0	0
Purchase of fixed assets
526	891	499	656	299	304	1,148	4,742	676	-	-	-	-	-	-	-	-
Purchase of fixed assets - construction-in-process
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Net cash provided by investing activities
-526	-1,391	-899	4,198	12,001	4,696	10,352	-2,740	-11,751	7,433	-15,872	-20,238	-375	-	-	-	-
Cash Flows from Financing Activities:
Proceeds from Horizon Notes
0	0	0	1,387	13,613	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from Fortress Note
-	-	-	-	-	-	-	-	-	-	-	-	-	258	662	720	581
Net cash used in investing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Payment of Fortress Note
-	-	-	-	-	-	-	-	-	0	0	0	320	-1,532	3,533	0	0
Proceeds from Horizon Note, net of debt discount
-	-	-	-	-	-	-	-	0	0	62	-8	50,242	23,925	11,083	0	0
Proceeds from exercise of warrants
0	0	0	0	0	0	0	85	96	0	0	0	0	-	-	-	-
Proceeds from issuance of common shares - At-the-Market Offering
4,997	0	0	22,515	0	-	-	-	-	-	-	-	-	-	-	-	-
Offering costs for the issuance of common shares - At-the-Market Offering
87	0	0	543	0	-	-	-	-	-	-	-	-	-	-	-	-
Proceeds from issuance of common shares under ESPP
169	-	-	-	0	-	-	-	-	-	-	-	-	-	-	-	-
Net cash provided by financing activities
5,079	0	-111	51,614	13,613	0	0	85	96	0	62	-8	49,922	-	-	-	-
Net change in cash, cash equivalents and restricted cash
-5,599	-	-	-	19,131	-	-	-	-	-	-	-	-	-	-	-	-
Net change in cash, cash equivalents and restricted cash
-	-	-	-	-	-	-	-6,011	-17,220	2,266	-20,581	-21,220	47,511	-	-	-	-
Net cash provided by financing activities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	720	581
Net change in cash
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0
Supplemental disclosure of cash flow information:
Cash paid for interest
341	359	357	341	0	0	0	0	0	0	0	0	413	-	-	-	-
Cash paid for interest
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0	0
Supplemental disclosure of noncash investing and financing activities:
Fixed assets (acquired but not paid)
540	-101	105	-8	191	71	-693	-1,502	2,320	-	-	-	-	-	-	-	-
Construction-in-progress included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	0	-	-	-	-
Issuance of common shares - Founders Agreement
4,923	0	0	0	2,085	0	0	0	9,558	0	0	0	4,396	0	0	0	190
Research and development licenses included in accounts payable and accrued expenses
250	-500	300	-50	250	-	-	-	-	-	-	-	-	-	-	-	-
Research and development licenses included in accounts payable and accrued expenses
-	-	-	-	-	-	-	-	0	-	-	-	-	-	-	-	-
Issuance of warrants - Horizon Notes
0	0	0	0	888	0	0	0	0	-	-	-	-	-	-	-	-
Common shares issuable for license acquired
-	-	-	-	-	-	-	-	-	-	0	0	1,682	-	-	-	-
Common shares issuable for license acquired
-	-	-	-	-	-	-	-	-	-	-	-	-	0	0	0	0